Immunization

Study authors conclude that all children should be up to date with recommended COVID-19 vaccines and initiate the vaccination process immediately when products become available.

Resources with pertinent information are essential in motivating individuals to comply with vaccine recommendations.

The CDC and WHO are currently tracking several variants that are driving the majority of new cases around the world.

The respiratory syncytial virus vaccine (Abrysvo) is the first and only maternal RSV vaccine used to help protect infants from the virus.

Receiving the vaccine during pregnancy is cited as crucial for both confronting disproportionate infant vulnerability and easing the disease burden for new and expecting mothers.

PXVX0317 has received Fast Track and Breakthrough Therapy designation from the FDA.

Moderna’s mRNA-1273 vaccine was associated with a lower risk of diagnosed COVID-19 when compared to Pfizer’s BNT162b2.

A Q&A with Marc Ost, co-owner of Eric’s RX Shoppe, which was one of the first community pharmacies to receive the new vaccine.

According to the CDC, HPV is the most commonly sexually transmitted infection in the US, with a prevalence of 45.2% of men and 39.9% of women aged 18-59 in 2013-2014.

Demetre Daskalakis, MD, MPH, urged those in the LGBTQ+ community to get fully vaccinated against the disease.

The report references adult vaccines, in terms of volume of use, for influenza, diphtheria and tetanus (Td), diphtheria, tetanus and pertussis (TDaP), hepatitis B, herpes zoster and pneumococcal.

By educating patients and administering vaccinations, these key health care providers can help prevent new cases from occurring.

A Western Australian study found the influenza vaccine has a possible protective effect against hospitalization for respiratory syncytial virus (RSV).

Heterologous vaccination—or mixing different vaccines—was safe and effective with Novavax and provided enhanced protection against the Omicron variant, a new study found.

The first RSV vaccines were approved by the FDA earlier this year.

A recent review evaluated possible approaches for new vaccines targeting respiratory viruses.

The VRBPAC committee voted 21-0 in favor of this recommendation.

Abrysvo is the second RSV vaccine approved by the FDA.

New data from Digestive Disease Week furthers evidence that biologics can be effective

Data presented at Digestive Disease Week show that patients with IBD had less intense post-vaccination symptoms after a fourth dose.

Seasonal influenza kills hundreds of thousands of people every year due to a constantly changing virus and highly inefficient vaccine production. A universal flu vaccine could deal with the first problem, and mRNA technology with the second.

How much progress have we made in developing therapies to treat this common childhood respiratory disorder?

Unvaccinated patients who were older at MG onset and at SARS-CoV-2 infection had more severe cases.

The Ghana Food and Drugs Authority approved R21 for children aged five months to three years.

The vaccine is approved for use in adults aged 60 and older to prevent lower respiratory tract disease caused by RSV.

Two RSV vaccines for seniors have completed phase 3 trials and demonstrated beneficial results. The public still awaits FDA decisions on potential approvals for both.

Post-COVID-19 conditions were more common in unvaccinated children than in children who had received at least 1 dose of a COVID-19 vaccine.

Monovalent vaccines by these manufacturers are no longer authorized for use in the United States.